Humasis Co. Ltd. (KOSDAQ:205470)

Market Cap	95.28B -52.5%
Revenue (ttm)	35.60B +114.9%
Net Income	-37.58B
EPS	-364.96
Shares Out	113.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,854,602
Average Volume	1,463,598
Open	910.00
Previous Close	916.00
Day's Range	840.00 - 916.00
52-Week Range	840.00 - 1,945.00
Beta	0.10
RSI	24.47
Earnings Date	Mar 13, 2026

About Humasis

Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women’s health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface proteins, COVID-19 RT-PCR kit, and COVID-19 Variant RT-qPCR kit, as well as MPXV real time PCR kit, a real-time polymerase chain reaction assay for the quali...

• Industry: Medical - Equipment & Services
• Sector: Healthcare
• Founded: 2000
• Employees: 69
• Stock Exchange: KOSDAQ
• Ticker Symbol: 205470

Financial Performance

In 2024, Humasis's revenue was 25.41 billion, an increase of 83.79% compared to the previous year's 13.83 billion. Losses were -30.44 billion, -45.08% less than in 2023.